Sarepta Therapeutics, Inc.
General ticker "SRPT" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $5.7B (TTM average)
Sarepta Therapeutics, Inc. does not follow the US Stock Market performance with the rate: -9.7%.
Estimated limits based on current volatility of 4.5%: low 20.36$, high 22.26$
Factors to consider:
- Total employees count: 1372 (+4.4%) as of 2024
- US accounted for 43.0% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Intellectual property risks, Labor/talent shortage/retention, Geopolitical risks, Cybersecurity threats, Operational and conduct risks
- Current price 64.2% below estimated low
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [63.78$, 143.68$]
- 2025-12-31 to 2026-12-31 estimated range: [54.76$, 124.99$]
Financial Metrics affecting the SRPT estimates:
- Negative: with PPE of 41.4 at the end of fiscal year the price was very high
- Negative: Operating cash flow per share per price, % of -1.79 <= 0.33
- Positive: 7.86 < Operating profit margin, % of 11.47
- Positive: 18.93 < Shareholder equity ratio, % of 38.55 <= 41.86
- Negative: Inventory ratio change, % of 6.60 > 0.84
- Positive: 1.87 < Return on assets ratio (scaled to [-100,100]) of 5.60
- Negative: negative Industry operating cash flow (median)
- Negative: -0.15 < Industry inventory ratio change (median), % of 0
Short-term SRPT quotes
Long-term SRPT plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $933.01MM | $1,243.34MM | $1,901.98MM |
| Operating Expenses | $1,469.21MM | $1,511.16MM | $1,683.90MM |
| Operating Income | $-536.20MM | $-267.82MM | $218.08MM |
| Non-Operating Income | $-153.76MM | $-252.27MM | $42.69MM |
| Interest Expense | $53.25MM | $22.01MM | $18.39MM |
| R&D Expense | $877.09MM | $877.39MM | $804.52MM |
| Income(Loss) | $-689.96MM | $-520.10MM | $260.77MM |
| Taxes | $13.53MM | $15.88MM | $25.54MM |
| Profit(Loss)* | $-703.49MM | $-535.98MM | $235.24MM |
| Stockholders Equity | $384.95MM | $859.34MM | $1,527.74MM |
| Inventory | $203.97MM | $322.86MM | $749.96MM |
| Assets | $3,128.37MM | $3,264.58MM | $3,963.17MM |
| Operating Cash Flow | $-325.35MM | $-500.99MM | $-205.79MM |
| Capital expenditure | $32.25MM | $87.34MM | $136.96MM |
| Investing Cash Flow | $-1,046.88MM | $-165.80MM | $755.56MM |
| Financing Cash Flow | $232.51MM | $125.00MM | $124.81MM |
| Earnings Per Share** | $-8.03 | $-5.80 | $2.47 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.